BioMimetic Therapeutics, a designer of bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, registered for an initial public offering Friday morning. Deutsche Bank and Pacific Growth Equities head the quartet of underwriters on the deal. Terms and timing have yet to be disclosed.
